Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

References

• Sarkodie SA, Owusu PA. Global assessment of environment, health and economic impact of the novel coronavirus (COVID-19). Environ Dev Sustain. 2021;23(4):5005–5011.
   PubMed Web of Science ®Google Scholar
• Kaye AD, Okeagu CN, Pham AD, et al. Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives. Best Practice & Research Clinical Anaesthesiology. 2020;35(3):293–306.
   Web of Science ®Google Scholar
• Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg. 2020;78:185–193.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention: COVID Data Tracker United States COVID-19 Cases, Deaths, and Laboratory Testing (NAATs) by State, Territory, and Jurisdiction [Internet]. 2021 [updated 2021 July 3; cited 2021 July 5]. Available from: https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days.
   Google Scholar
• Centers for Disease Control and Prevention: COVID Data Tracker United States – New Admissions of Patients with Confirmed COVID-19 [Internet]. [updated 2021. July 19; cited 2021 July 22]. Available from: https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions.
   Google Scholar
• Centers for Disease Control and Prevention: COVID Data Tracker United States – COVID-19 Vaccinations in the United States [Internet]. 2021 [updated 2021 November 7; cited 2021 November 8]. Available from: https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-fully-percent-pop12.
   Google Scholar
• Centers for Disease Control and Prevention: COVID Forecasts: Hospitalizations – Reported and forecasted new COVID-19 hospital admissions as of November 1, 2021. [Internet]. [updated 2021 November 3; cited 2021 November 3]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/hospitalizations-forecasts.html.
   Google Scholar
• Centers for Disease Control and Prevention: COVID Data Tracker United States – COVID-19 Hospitalizations and Disease Severity [Internet]. [updated 2021. July 19; cited 2021 July 22]. Available from: https://covid.cdc.gov/covid-data-tracker/#hospitalizations-severity.
   Google Scholar
• Rae M, Claxton G, Kurani N, et al. Potential costs of COVID-19 treatment for people with employer coverage [updated March 13, 2021; July 6, 2021]. Available from: https://www.healthsystemtracker.org/brief/potential-costs-of-coronavirus-treatment-for-people-with-employer-coverage/.
   Google Scholar
• Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24(1):308–317.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service (FFS) Billing. July 2, 2021. p. 1–180.
   Google Scholar
• Sheinson D, Dang J, Shah A, et al. A Cost-Effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021;38(4):1811–1831.
   PubMed Web of Science ®Google Scholar
• Goletti D, Cantini F. Baricitinib therapy in covid-19 Pneumonia – an unmet need fulfilled. N Engl J Med. 2021;384(9):867–869.
   PubMed Web of Science ®Google Scholar
• Liu C-H, Lu C-H, Wong SH, et al. Update on antiviral strategies against COVID-19: unmet needs and prospects [review]. Front Immunol. 2020;11(3845):616595.
   PubMedGoogle Scholar
• Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2021. DOI:10.1016/S2213-2600(21)00494-X
   PubMedGoogle Scholar
• Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761–770.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998–1002.
   Web of Science ®Google Scholar
• Kox M, Waalders NJB, Kooistra EJ, et al. Cytokine levels in critically ill patients with COVID-19 and other conditions. Jama. 2020;324(15):1565–1567.
   PubMed Web of Science ®Google Scholar
• Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021;6(57):eabg9873.
   PubMed Web of Science ®Google Scholar
• Novack V, Beitler JR, Yitshak-Sade M, et al. Alive and ventilator free: a hierarchical, composite outcome for clinical trials in the acute respiratory distress syndrome. Crit Care Med. 2020;48(2):158–166.
   PubMed Web of Science ®Google Scholar
• Temesgen Z, Kelley CF, Cerasoli F, et al. Early lenzilumab treatment of COVID-19 patients using C-Reactive protein as a biomarker improves efficacy: results from the phase 3 'AIR’. Trial. medRxiv. 2022. DOI:10.1101/2021.12.30.21267140
   Google Scholar
• Lavillegrand JR, Garnier M, Spaeth A, et al. Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann Intensive Care. 2021;11(1):9.
   PubMed Web of Science ®Google Scholar
• Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York city: prospective cohort study. Bmj. 2020;369:m1966.
   PubMed Web of Science ®Google Scholar
• Humanigen: Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients [Internet]. [updated 2021 August 4; cited 2021 September 24]. Available from: https://ir.humanigen.com/English/news/news-details/2021/Lenzilumab-TreatmentMay-Provide-Enhanced-Likelihood-of-Survival-Without-Ventilation-in-Hospitalized-Black-and-African-American-COVID-19-Patients/default.aspx.
   Google Scholar
• Centers for Disease Control and Prevention: Risk for COVID-19 Infection, Hospitalization, and Death by Race/Ethnicity [Internet]. [updated 2021 September 9; cited 2021 September 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html#print.
   Google Scholar
• Ndugga N, Hill L, Artiga S. Latest Data on COVID-19 Vaccinations by Race/Ethnicity [Internet]. [updated 2021 September 22; cited September 24]. Available from: https://www.kff.org/coronavirus-covid-19/issue-brief/latest-data-on-covid-19-vaccinations-race-ethnicity/.
   Google Scholar
• Centers for Disease Control and Prevention: People with Certain Medical Conditions [Internet]. [updated 2021 August 20; cited 2021 September 24]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html.
   Google Scholar
• Rodriguez F, Solomon N, de Lemos JA, et al. Racial and ethnic differences in presentation and outcomes for patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 cardiovascular disease registry. Circulation. 2021;143(24):2332–2342.
   PubMed Web of Science ®Google Scholar
• Chastain DB, Osae SP, Henao-Martinez AF, et al. Racial disproportionality in covid clinical trials. N Engl J Med. 2020;383(9):e59.
   PubMed Web of Science ®Google Scholar
• United States Census Bureau: QuickFacts Table [Internet]. [updated 2020. cited 2021 September 24]. Available from: https://www.census.gov/quickfacts/fact/table/US/RHI225219#qf-headnote-a.
   Google Scholar
• National Institutes of Health: COVID-19 Treatment Guidelines – Therapeutic Management of Hospitalized Adults with COVID-19 [Internet]. [updated 2021 July 8; cited 2021 July 22]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults–therapeutic-management/.
   Google Scholar
• ClinicalTrials.gov: ACTIV-5/Big Effect Trial (BET-B) for the Treatment of COVID-19 [Internet]. [updated 2021 September 22; cited 2021 September 24]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04583969.
   Google Scholar
• Humanigen. Additional data analyses for LIVE-AIR Phase 3 randomized double-blind placebo-controlled trial. Data on file. 2021.
   Google Scholar
• Bureau of Labor Statistics: CPI-All Urban Consumers (Current Series); Medical care in U.S. city average, all urban consumers, not seasonally adjusted [Internet]. [updated 2021 April; cited 2021 June 3]. Available from: https://data.bls.gov/cgi-bin/surveymost?cu.
   Google Scholar
• Humanigen. Lenzilumab drug cost. Data on file. 2021.
   Google Scholar
• Food and Drug Administration: Fact Sheet for Healthcare Providers: Emergency Use Authorization for ACTEMRA® (tocilizumab) [Internet]. [updated 2021 June; cited 2021 November 10]. Available from: https://www.fda.gov/media/150321/download.
   Google Scholar
• Pricentric One by EVERSANA: MNF(WAC) price for ACTEMRA Infusion 1 vial 20 mL 400 mg [Internet]. [updated 2021 November 09. cited 2021 November 10]. Available from: https://pricentric.alscg.com/.
   Google Scholar
• Schmier J, Ogden K, Nickman N, et al. Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting. Clin Ther. 2017;39(8):1600–1617.
   PubMed Web of Science ®Google Scholar
• Wu N, Hanrahan J, Bornstein J, et al. Healthcare costs utilization and costs of patients hospitalized with acute respiratory distress syndrome (ARDS) in US commercially-insured individuals and medicare beneficiaries. Eur Respiratory Soc. 2015;46(59):PA2139.
   Web of Science ®Google Scholar
• Ruhl AP, Lord RK, Panek JA, et al. Health care resource use and costs of two-year survivors of acute lung injury. An observational cohort study. Ann Am Thorac Soc. 2015;12(3):392–401.
   PubMed Web of Science ®Google Scholar
• Hazard D, Kaier K, von Cube M, et al. Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach. BMC Med Res Methodol. 2020;20(1):206.
   PubMed Web of Science ®Google Scholar
• Luo X, Zhou W, Yan X, et al. Prognostic value of C-Reactive protein in patients with coronavirus 2019. Clin Infect Dis. 2020;71(16):2174–2179.
   PubMed Web of Science ®Google Scholar
• Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol. 2020;92(11):2409–2411.
   PubMed Web of Science ®Google Scholar
• Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2(10):e594–e602.
   PubMedGoogle Scholar
• Sharifpour M, Rangaraju S, Liu M, et al. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLOS One. 2020;15(11):e0242400.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention: Post-COVID Conditions [Internet]. [updated 2021 July 12; cited 2021 July 19]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html.
   Google Scholar
• Leung TYM, Chan AYL, Chan EW, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 2020;9(1):2190–2199.
   PubMed Web of Science ®Google Scholar
• Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–627.
   PubMed Web of Science ®Google Scholar
• Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020;8(1):8.
   PubMed Web of Science ®Google Scholar
• Lam MH, Wing YK, Yu MW, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169(22):2142–2147.
   PubMedGoogle Scholar
• Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after Infection. Sci Rep. 2017;7(1):9110.
   PubMed Web of Science ®Google Scholar
• King CS, Sahjwani D, Brown AW, et al. Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. PLOS One. 2020;15(11):e0242651.
   PubMed Web of Science ®Google Scholar
• Auld SC, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020;48(9):e799–e804.
   PubMed Web of Science ®Google Scholar
• Humanigen: FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients [Internet]. [updated 2021 September 9; cited 2021 September 24]. Available from: https://ir.humanigen.com/English/news/news-details/2021/FDA-has-declined-Humanigens-Emergency-Use-Authorization-EUA-Request-for-Lenzilumab-in-Hospitalized-COVID-19-Patients/default.aspx.
   Google Scholar
• Humanigen: Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved [Internet]. 2022 [updated 2022 January 5; cited 2022 January 6]. Available from: https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Announces-Target-Enrollment-in-Phase-23-ACTIV-5BET-B-Trial-of-Lenzilumab-for-the-Treatment-of-COVID-19-has-Been-Achieved/default.aspx.
   Google Scholar
• Shelburne P: Global Vaccine Tracking - Across the Globe, Rates of Vaccine Skepticism Have Stalled [Internet]. [updated 2021 November 4; cited November 8]. Available from: https://morningconsult.com/global-vaccine-tracking/.
   Google Scholar
• Centers for Disease Control and Prevention: Estimates of Vaccine Hesitancy for COVID-19 [Internet]. [cited 2021 November 2]. Available from: https://data.cdc.gov/stories/s/Vaccine-Hesitancy-for-COVID-19/cnd2-a6zw/.
   Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416.
   PubMed Web of Science ®Google Scholar
• Cohn BA, Cirillo PM, Murphy CC, et al. Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans. medRxiv. 2021. DOI:10.1101/2021.10.13.21264966
   Google Scholar
• Dolgin E. COVID vaccine immunity is waning – how much does that matter? Nature. 2021;597(7878):606–607.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention: What You Need to Know about Variants [Internet]. [updated 2021 November 1; cited 2021 November 2]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html.
   Google Scholar
• European Commission: European Health Union – Commission Establishes Portfolio of 10 Most Promising Treatments for COVID-19 [Internet]. [updated 2021 October 22. cited 2021 November 2]. Available from: https://ec.europa.eu/commission/presscorner/detail/en/IP_21_5366.
   Google Scholar